Eli Lilly and Company company logo

# 1st Gen Model Eli Lilly and Company Pharmaceutical preparations

63.38% successful of 71 deals
$83.51 Last close price
at 21-nov-2017


Model's trade recommendations 0.27% Return for period

1.89% Annual return

$91.27B Market Cap

β 0.34  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period 0.27%
52wk return 2.41%
52wk Range
Sortino ratio 0.31
Sharpe ratio 0.24
Norm. RMSE 0.41%
Downside risk 5.90%
Volatility 7.82%
  • 2.08 (2.51%) Div (Yield)
  • BUY Analysts consensus recommendation

Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products. The company directs its research efforts primarily toward the search for products to diagnose, prevent and treat human diseases. The company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Eli Lilly and Company (LLY) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 22, 2015.

Market data for LLY model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 1099M
P/E 20.27
Shares Outstanding 1101M
% Held by Insiders 0.20%
% Held by Institutions 76.61%
EPS (last reported FY) $3.52
EPS (last reported Q) $1.05
EPS, estimated (last reported Q) $1.03
Total revenues $21 B
Net income $3 B